Literature DB >> 2187701

Comparison of the renal effects of dilevalol and carteolol in patients with mild to moderate essential hypertension.

T Baba1, S Murabayashi, T Tomiyama, K Takebe.   

Abstract

The effects of 6 weeks of treatment with dilevalol 100 mg once daily, or carteolol 10 mg once daily, on renal blood flow (RBF), glomerular filtration rate (GFR) and total renal vascular resistance (TRR) were studied in 10 patients with mild-to-moderate essential hypertension in a randomised cross-over experiment. Both drugs lowered the systolic and diastolic blood pressures to a similar extent without altering the heart rate. Carteolol non-significantly decreased RBF by 9.2% and GFR by 12.3% without altering. TRR, whereas dilevalol produced a significant reduction in TRR by 13.2% (p less than 0.05), a non-significant decrease in RBF by 4.6% and no change in GFR. Neither drug changed plasma osmotic pressure, serum total protein concentration, electrolytes or plasma aldosterone concentration. Plasma renin activity tended to be lower in the dilevalol phase as compared to the carteolol phase. The results suggest that dilevalol may cause a greater decrease in TRR and less reduction in GFR when compared to carteolol in patients with mild-to-moderate essential hypertension. The difference in the renal effects might be due to the difference in the potency of vasodilatory properties of both drugs at the doses applied.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2187701     DOI: 10.1007/bf00315037

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  23 in total

1.  Evaluation of renal resistances, with special reference to changes in essential hypertension.

Authors:  D M GOMEZ
Journal:  J Clin Invest       Date:  1951-10       Impact factor: 14.808

2.  Effects of dilevalol, an R, R-isomer of labetalol, on blood pressure and renal function in patients with mild-to-moderate essential hypertension.

Authors:  T Baba; S Murabayashi; K Aoyagi; T Ishizaki
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  A non-chromatographic non-extraction radioimmunoassay for serum aldosterone.

Authors:  T Ogihara; K Iinuma; K Nishi; Y Arakawa; A Takagi
Journal:  J Clin Endocrinol Metab       Date:  1977-10       Impact factor: 5.958

4.  Effect of carteolol on renal function in healthy subjects and patients with hypertension.

Authors:  K Tabei; H Furuya; Y Asano; S Hosoda
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

6.  Redistribution of cardiac output to the kidneys during oral nadolol administration.

Authors:  S C Textor; F M Fouad; E L Bravo; R C Tarazi; D G Vidt; R W Gifford
Journal:  N Engl J Med       Date:  1982-09-02       Impact factor: 91.245

7.  Comparison of dewpoint and freezing point osmometry.

Authors:  D E Mercier; R D Feld; D L Witte
Journal:  Am J Med Technol       Date:  1978-11

8.  Effects of pindolol on renal function.

Authors:  E Wainer; G Boner; J B Rosenfeld
Journal:  Clin Pharmacol Ther       Date:  1980-11       Impact factor: 6.875

9.  Renal haemodynamics after chronic treatment with labetalol and propranolol.

Authors:  P L Malini; E Strocchi; S Negroni; E Ambrosioni; B Magnani
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

10.  Cardiovascular studies of 5-(3-tert-butylamino-2-hydroxy) propoxy-3,4-dihydrocarbostyril hydrochloride (OPC-1085), a new potent beta-adrenergic blocking agent.

Authors:  Y Yabuochi; D Kinoshita
Journal:  Jpn J Pharmacol       Date:  1974-12
View more
  2 in total

Review 1.  Influence of antihypertensive therapy on renal function.

Authors:  U Frei; R Schindler; K M Koch
Journal:  Clin Investig       Date:  1992

2.  Beta-blockers in hypertension: truths and half-truths.

Authors:  C Venkata S Ram
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-07       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.